Alterations in Spinal Cord Metabolism during Treatment of Neuropathic Pain.
J Neuroimmune Pharmacol
; 10(3): 396-401, 2015 Sep.
Article
em En
| MEDLINE
| ID: mdl-26232265
ABSTRACT
Therapeutic options for neuropathic pain have improved over the last 20 years yet still only provide partial relief with numerous side effects. Recently, metabolomics revealed that the concentration of the endogenous metabolite N,N-dimethylsphingosine (DMS) is increased in the spinal cord in a model of neuropathic pain. Additionally, it was shown that introduction of DMS to the central nervous system (CNS) resulted in mechanical allodynia. Here, we have examined two compounds; pregabalin (Lyrica®), a drug used to treat neuropathic pain, and N-oleoylethanolamine (NOE), an endogenous endocannabinoid-like compound that is known to affect multiple lipid pathways. We found that the concentration of DMS in the spinal cord was not significantly altered upon pregabalin treatment of rats suffering from neuropathic pain. We further explored whether modulating lipid metabolism may impact neuropathic pain by testing NOE as a potential novel therapeutic.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Esfingosina
/
Medula Espinal
/
Ácidos Oleicos
/
Endocanabinoides
/
Etanolaminas
/
Agonistas de Receptores de Canabinoides
/
Pregabalina
/
Analgésicos
/
Neuralgia
Limite:
Animals
Idioma:
En
Revista:
J Neuroimmune Pharmacol
Assunto da revista:
ALERGIA E IMUNOLOGIA
/
FARMACOLOGIA
/
NEUROLOGIA
Ano de publicação:
2015
Tipo de documento:
Article
País de afiliação:
Estados Unidos